264 related articles for article (PubMed ID: 15544435)
1. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
[TBL] [Abstract][Full Text] [Related]
3. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
Zhou SF; Xue CC; Yu XQ; Li C; Wang G
Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
[TBL] [Abstract][Full Text] [Related]
4. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
Zhou SF
Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
[TBL] [Abstract][Full Text] [Related]
5. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.
Zhou SF
Curr Pharm Des; 2008; 14(10):990-1000. PubMed ID: 18473851
[TBL] [Abstract][Full Text] [Related]
6. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.
Zhou S; Chan E; Li X; Huang M
Ther Clin Risk Manag; 2005 Mar; 1(1):3-13. PubMed ID: 18360537
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Dresser GK; Spence JD; Bailey DG
Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
[TBL] [Abstract][Full Text] [Related]
10. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
[TBL] [Abstract][Full Text] [Related]
11. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
Ohno Y; Hisaka A; Suzuki H
Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes.
Masubuchi Y; Horie T
Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281
[TBL] [Abstract][Full Text] [Related]
13. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.
Chan WK; Delucchi AB
Life Sci; 2000 Nov; 67(25):3103-12. PubMed ID: 11125847
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro.
Polasek TM; Elliot DJ; Lewis BC; Miners JO
J Pharmacol Exp Ther; 2004 Dec; 311(3):996-1007. PubMed ID: 15304522
[TBL] [Abstract][Full Text] [Related]
16. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
17. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
Potęga A; Fedejko-Kap B; Mazerska Z
Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
[TBL] [Abstract][Full Text] [Related]
18. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
Lin HL; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2002 Apr; 301(1):160-7. PubMed ID: 11907170
[TBL] [Abstract][Full Text] [Related]
20. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
